These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32187094)

  • 1. CORR Insights®: Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
    Damron TA
    Clin Orthop Relat Res; 2020 May; 478(5):1086-1088. PubMed ID: 32187094
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
    Tsukamoto S; Tanaka Y; Mavrogenis AF; Kido A; Kawaguchi M; Errani C
    Clin Orthop Relat Res; 2020 May; 478(5):1076-1085. PubMed ID: 31794487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
    J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
    Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
    Chinder PS; Hindiskere S; Doddarangappa S; Pal U
    Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
    Urakawa H; Yonemoto T; Matsumoto S; Takagi T; Asanuma K; Watanuki M; Takemoto A; Naka N; Matsumoto Y; Kawai A; Kunisada T; Kubo T; Emori M; Hiraga H; Hatano H; Tsukushi S; Nishida Y; Akisue T; Morii T; Takahashi M; Nagano A; Yoshikawa H; Sato K; Kawano M; Hiraoka K; Tanaka K; Iwamoto Y; Ozaki T
    World J Surg Oncol; 2018 Aug; 16(1):160. PubMed ID: 30089488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
    Errani C; Tsukamoto S; Leone G; Righi A; Akahane M; Tanaka Y; Donati DM
    J Bone Joint Surg Am; 2018 Mar; 100(6):496-504. PubMed ID: 29557866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
    World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery.
    Asano N; Saito M; Kobayashi E; Morii T; Kikuta K; Watanabe I; Anazawa U; Takeuchi K; Suzuki Y; Susa M; Nishimoto K; Ishii R; Miyazaki N; Mrioka H; Kawai A; Horiuchi K; Nakayama R
    Ann Surg Oncol; 2022 Jun; 29(6):3992-4000. PubMed ID: 35175454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASO Author Reflections: Preoperative Denosumab May Increase the Risk of Local Recurrence of Giant Cell Tumor of Bone after Curettage Surgery.
    Asano N; Horiuchi K
    Ann Surg Oncol; 2022 Jun; 29(6):4001. PubMed ID: 35169975
    [No Abstract]   [Full Text] [Related]  

  • 11. CORR Insights®: Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
    Ferguson PC
    Clin Orthop Relat Res; 2020 Nov; 478(11):2534-2536. PubMed ID: 32732739
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
    Tsukamoto S; Hindiskere S; Honoki K; Mavrogenis AF; Tanaka Y; Chinder PS; Donati DM; Errani C
    Int Orthop; 2023 Jan; 47(1):265-273. PubMed ID: 36282294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone.
    Puri A; Gulia A; Hegde P; Verma V; Rekhi B
    Bone Joint J; 2019 Feb; 101-B(2):170-177. PubMed ID: 30700112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between preoperative denosumab and the risk of local recurrence in patients with giant cell tumor of bone: A meta-analysis and systematic review.
    Sun Z; Wu Z; Zhang L; Jia Q; Zhou Z; Xiao J
    J Cancer Res Ther; 2023 Feb; 19(1):25-33. PubMed ID: 37006039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
    Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
    Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610.
    Urakawa H; Mizusawa J; Tanaka K; Eba J; Hiraga H; Kawai A; Nishida Y; Hosaka M; Iwamoto Y; Fukuda H; Ozaki T
    Jpn J Clin Oncol; 2019 Apr; 49(4):379-382. PubMed ID: 30796832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis.
    Chen X; Li H; Zhu S; Wang Y; Qian W
    BMC Musculoskelet Disord; 2020 Apr; 21(1):256. PubMed ID: 32312263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab Does Not Decrease Local Recurrence in Giant Cell Tumor of Bone Treated With En Bloc Resection.
    Tsukamoto S; Mavrogenis AF; Tanaka Y; Kido A; Kawaguchi M; Errani C
    Orthopedics; 2021; 44(6):326-332. PubMed ID: 34618637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
    Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab.
    Aponte-Tinao LA; Piuzzi NS; Roitman P; Farfalli GL
    Clin Orthop Relat Res; 2015 Sep; 473(9):3050-5. PubMed ID: 25758379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.